ArticleAmerican journal of respiratory and critical care medicine2025
Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease.
Abstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The Role of Integrin Family in Atherosclerotic Cardiovascular Disease: A Prospective Cohort Study and Mendelian Randomization Analysis.Biomedicines · 2026Article
- Integrated imaging-informed and machine learning-based prognostic models for risk stratification in connective tissue disease-associated interstitial lung disease: a multicenter study.Clinical rheumatology · 2026Article
- Molecular endotypes predict differential response to immunosuppressant therapy in non-idiopathic pulmonary fibrosis interstitial lung disease.American journal of respiratory and critical care medicine · 2026Observational
- Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation Analysis.Research square · 2026Article
- Current concepts in the diagnosis and treatment of hypersensitivity pneumonitis: a narrative review.Respiratory research & clinical practice · 2026Review
- Beyond Labels: Can Biomarkers and Treatable Traits Revolutionize Interstitial Lung Disease Care?Biomedicines · 2025Article
- Precision medicine in rheumatoid arthritis-associated interstitial lung disease: current evidence and future directions.Current opinion in pulmonary medicine · 2025Review
- Moving past multidisciplinary discussions and Gender-Age-Physiology model: precision medicine through biological phenotyping in interstitial lung disease.Current opinion in pulmonary medicine · 2025Review
- Blurred Boundaries: Rethinking Disease Classifications in Interstitial Lung Disease Using Molecular Signals.American journal of respiratory and critical care medicine · 2025Article
- Endotypes and Phenotypes in ILD: Is It Time to Reclassify ILD by Risk Stratification?Biomedicines · 2025Article
- Advances in the research and application of stem cell therapies for idiopathic pulmonary fibrosis.American journal of clinical and experimental immunology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
18 authors.
Shehabaldin AlqalyoobiDivision of Pulmonary and Critical Care Medicine, East Carolina University, Greenville, North Carolina.ORCID 0000-0001-5602-2725
Jennifer A SmithDepartment of Epidemiology.
Manoj V MaddaliDivision of Pulmonary, Allergy, and Critical Care Medicine and.
Janelle Vu PugashettiDivision of Pulmonary and Critical Care Medicine, and.ORCID 0000-0002-8889-2757
Chad A NewtonDivision of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-5256-9029
John S KimDivision of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, Virginia.
Angela L LinderholmDivision of Pulmonary, Critical Care and Sleep Medicine, University of California, Davis, Sacramento, California.
Ching-Hsien ChenDivision of Pulmonary, Critical Care and Sleep Medicine, University of California, Davis, Sacramento, California.ORCID 0000-0002-4211-9988
Shwu-Fan MaDivision of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, Virginia.ORCID 0000-0002-3058-9480
Swaraj BoseDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan.
Susan MurrayDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan.
Ayodeji AdegunsoyeSection of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois.
Mary E StrekSection of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois.
Christine Kim GarciaDivision of Pulmonary and Critical Care Medicine, Columbia University, New York, New York.ORCID 0000-0002-0771-1249
Paul J WoltersDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, San Francisco, California; and.
Fernando J MartinezUniversity of Massachusetts, Boston, Massachusetts.
Imre NothDivision of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Justin M OldhamDepartment of Epidemiology.ORCID 0000-0003-4957-8869
Funding
POSTDOCTORAL TRAINING IN MEDICAL INFORMATION SCIENCEST15LM007033 · NLM · STANFORD UNIVERSITY · PI SYLVIA KATINA PLEVRITIS · 1985 to 2026
$25.5MPULMONARY CELLULAR AND MOLECULAR BIOLOGY TRAININGT32HL007749 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Pickett Dickson · 1993 to 2026
$19.9M1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUH3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2021 to 2025
$11.6MPulmonary Fibrosis and Telomerase DysfunctionR01HL093096 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI GARCIA, CHRISTINE KIM · 2009 to 2024
$6.9MLung Remodeling Mediated by Telomere Dysfunction in Alveolar Type II CellsR01HL139897 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Paul j WOLTERS · 2018 to 2026
$5.5MProteomic Profiling of Idiopathic Pulmonary Fibrosis Progression TrajectoryR01HL169166 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2023 to 2026
$2.7MPrognostic Biomarker Development in Progressive Fibrosing Interstitial Lung DiseaseR01HL166290 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2024 to 2026
$2.2M1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUG3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2019 to 2019
$977kMolecular Markers of Idiopathic Pulmonary Fibrosis ProgressionK23HL148498 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI NEWTON, CHAD ALAN · 2020 to 2024
$891kRole of polyunsaturated fatty acids in pulmonary fibrosisK23HL150301 · NHLBI · UNIVERSITY OF VIRGINIA · PI KIM, JOHN S · 2021 to 2025
$858kImproving Pulmonary Fibrosis Classification with Genomics Informed Phenotypic ClustersK23HL146942 · NHLBI · UNIVERSITY OF CHICAGO · PI ADEGUNSOYE, AYODEJI · 2020 to 2024
$810kA Multi-Dimensional Signature to Predict Treatment Failure in Patients with Connective Tissue Disease-Associated Interstitial Lung DiseaseK23HL171871 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Janelle Vu Pugashetti · 2025 to 2026
$392kNHLBI NIH HHS K23 HL146942NHLBI NIH HHS K23HL146942NHLBI NIH HHS K23 HL148498NHLBI NIH HHS K23 HL150301NHLBI NIH HHS K23 HL171871NHLBI NIH HHS L30 HL181822NHLBI NIH HHS R01 HL093096NHLBI NIH HHS R01 HL139897NHLBI NIH HHS R01 HL166290NHLBI NIH HHS R01 HL169166NHLBI NIH HHS T32 HL007749NHLBI NIH HHS UG3 HL145266NHLBI NIH HHS UH3 HL145266NLM NIH HHS T15 LM007033
Abstract
PubMed holds no abstract for this paper.
Indexed as
Lung Diseases, InterstitialProteomicsAgedBiomarkersCaliforniaFemaleHumansIdiopathic Pulmonary FibrosisMaleMiddle AgedProportional Hazards ModelsProspective StudiesBiomarkersbiomarkerconnective tissue diseaseinterstitial lung diseaseproteomicssurvival
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.